Q-omics provides the consensus-scored KLF3P1 profile across patient tissues and cancer cell-line models. KLF3P1 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in CHOL. Among the 18 cancer types available for tumor–normal comparison, KLF3P1 is differentially expressed in 6, with the highest sampling consensus in KIRC. Additionally, KLF3P1 RNA expression shows 9,860 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight CHOL, KIRC, and GBM as cancer lineages where KLF3P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KLF3P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KLF3P1 survival associations across molecular data types. KLF3P1 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KLF3P1 RNA expression–survival associations across cancer types. High KLF3P1 expression shows unfavorable associations in CHOL, LGG, UCS, READ and DLBC, but favorable associations in BRCA. The CHOL Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .010). Together, the overview and detailed table identify CHOL as the clearest survival context for KLF3P1 RNA expression.
This table summarizes KLF3P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for KLF3P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KLF3P1 shows lower tumor expression in KICH and higher tumor expression in KIRC, HNSC, COAD, CHOL and LIHC. The KIRC box plot shows higher KLF3P1 RNA expression in tumor versus normal tissue (log2 FC = +0.024, t-test p = .005).
This table shows molecular features associated with KLF3P1 in patient tissues and cancer cell lines. In patient samples, KLF3P1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
